First-in-Human trial tests 'Living Drug' for devastating autoimmune conditions
NCT ID NCT07095075
Summary
This is a very early study to test the safety and initial effects of a new treatment called LUCAR-DKS1. It is for adults with severe autoimmune diseases like lupus or scleroderma that have come back or not improved with standard treatments. The treatment involves giving patients specially engineered immune cells to try to control their disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangsu Province Hospital
RECRUITINGNanjing, Jiangsu, 210029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
Contact
-
The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
RECRUITINGHefei, Anhui, 230036, China
Contact
-
The First Affiliated Hospital of Wenzhou Medical University
NOT_YET_RECRUITINGWenzhou, Zhejiang, 325015, China
Contact
Contact
-
The Third The People's Hospital of BengBu
NOT_YET_RECRUITINGBengbu, Anhui, 233000, China
Contact
Conditions
Explore the condition pages connected to this study.